Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in de Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation

BackgroundA recent randomized phase III study of 719 de novo liver transplant recipients showed that early everolimus plus reduced-dose tacrolimus (EVR + rTAC) led to significantly better kidney function than standard TAC (TAC-C), without compromising efficacy. In that study, patients from North Ame